A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

This early-phase study tests a three-drug combination — ziftomenib (a menin inhibitor), venetoclax (a BCL-2 inhibitor), and azacitidine (a chemotherapy drug) — in patients with acute myeloid leukemia (AML) that has specific genetic mutations or has come back after treatment. **You may be eligible if...** - You have been diagnosed with AML - Your leukemia has a specific genetic mutation (such as NPM1 mutation or KMT2A rearrangement), OR your AML has returned or not responded to prior treatment - You are at least 18 years old with adequate liver and kidney function - You have not received prior menin inhibitor therapy **You may NOT be eligible if...** - You have leukemia that has spread to the brain or spinal fluid - You have serious heart problems (QT prolongation) or active severe infections - You are pregnant or breastfeeding - You are unable to swallow oral medications Talk to your doctor to see if this trial is right for you.